Is CDK9 a promising target for both primary and metastatic osteosarcoma

T K Albert, C Rigault, J Eickhoff, K Baumgart, C Antrecht, B Klebl, G Mittler, M Meisterernst, Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor British Journal of Pharmacology. ,vol. 171, pp. 55- 68 ,(2014) , 10.1111/BPH.12408

Bin Shan, Ying Zhuo, Dawn Chin, Cindy A. Morris, Gilbert F. Morris, Joseph A. Lasky, Cyclin-dependent Kinase 9 Is Required for Tumor Necrosis Factor-α-stimulated Matrix Metalloproteinase-9 Expression in Human Lung Adenocarcinoma Cells * Journal of Biological Chemistry. ,vol. 280, pp. 1103- 1111 ,(2005) , 10.1074/JBC.M406293200

Marion Peyressatre, Camille Prével, Morgan Pellerano, May Morris, Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors Cancers. ,vol. 7, pp. 179- 237 ,(2015) , 10.3390/CANCERS7010179

Ryan A. Durfee, Maryam Mohammed, Hue H. Luu, Review of Osteosarcoma and Current Management Rheumatology and Therapy. ,vol. 3, pp. 221- 243 ,(2016) , 10.1007/S40744-016-0046-Y

Alexandra L. Thomas, Hanne Lind, Angela Hong, Danijela Dokic, Kailey Oppat, Elana Rosenthal, Amina Guo, Aaron Thomas, Randala Hamden, Jacqueline S. Jeruss, Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells Cell Cycle. ,vol. 16, pp. 1453- 1464 ,(2017) , 10.1080/15384101.2017.1338988

Silvia Boffo, Angela Damato, Luigi Alfano, Antonio Giordano, CDK9 inhibitors in acute myeloid leukemia. Journal of Experimental & Clinical Cancer Research. ,vol. 37, pp. 36- 36 ,(2018) , 10.1186/S13046-018-0704-8

Ashley J. Schlafstein, Allison E. Withers, Soumon Rudra, Diana Danelia, Jeffrey M. Switchenko, Donna Mister, Saul Harari, Hui Zhang, Waaqo Daddacha, Shahrzad Ehdaivand, Xiaoxian Li, Mylin A. Torres, David S. Yu, CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy. International journal of breast cancer. ,vol. 2018, pp. 6945129- 6945129 ,(2018) , 10.1155/2018/6945129

Hanghang Zhang, Somnath Pandey, Meghan Travers, Hongxing Sun, George Morton, Jozef Madzo, Woonbok Chung, Jittasak Khowsathit, Oscar Perez-Leal, Carlos A Barrero, Carmen Merali, Yasuyuki Okamoto, Takahiro Sato, Joshua Pan, Judit Garriga, Natarajan V Bhanu, Johayra Simithy, Bela Patel, Jian Huang, Noël J-M Raynal, Benjamin A Garcia, Marlene A Jacobson, Cigall Kadoch, Salim Merali, Yi Zhang, Wayne Childers, Magid Abou-Gharbia, John Karanicolas, Stephen B Baylin, Cynthia A Zahnow, Jaroslav Jelinek, Xavier Graña, Jean-Pierre J Issa, None, Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer Cell. ,vol. 175, pp. 1244- 1258 ,(2018) , 10.1016/J.CELL.2018.09.051

Junfen Xu, Shanshan Xu, Yifeng Fang, Tingting Chen, Xing Xie, Weiguo Lu, Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway. Iubmb Life. ,vol. 71, pp. 347- 356 ,(2018) , 10.1002/IUB.1983

Hangzhan Ma, Nicole A. Seebacher, Francis J. Hornicek, Zhenfeng Duan, Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. ,vol. 39, pp. 182- 193 ,(2019) , 10.1016/J.EBIOM.2018.12.022